| J Assoc Physicians India 2000 Sep;48(9):871-6
dietary fiber beneficial in chronic ischemic heart disease?
Vajifdar BU, Goyal VS, Lokhandwala YY, Mhamunkar SR, Mahadik
SP, Gawad AK, Halankar SA, Kulkarni HL.
Department of Cardiology, KEM Hospital, Mumbai.
OBJECTIVES: To evaluate the benefit of a dietary fiber preparation
(Fibernat) in patients with chronic ischemic heart disease (IHD).
METHODS: From January 1997 to March 1998, 114 consecutive patients
with chronic IHD were enrolled in this prospective double blind
randomized placebo controlled trial. The fiber (F) and placebo
(P) groups were comparable at baseline. All patients were given
advice regarding dietary and lifestyle modifications. Concomitant
drug therapy was not altered. The drug (consisting of soluble
and insoluble fibers obtained from fenugreek, guar gum and wheat
bran) and placebo were administered for six months (10 grams
twice daily). RESULTS: The following parameters improved in
both groups: HDL cholesterol (32 to 39 mg/dl, p < 0.0009
in F and 33 to 38, p < 0.007 in P), total: HDL cholesterol
ratio (6.7 to 5.6, p < 0.0007 in F and from 7.0 to 6.0, p
< 0.01 in P) and weight (64.0 to 63.0 kg, p < 0.002 in
F and 60.3 to 59.5, p < 0.002 in P). The Apolipoprotein B
increased (101 to 129 mg/dl, p < 0.00001 in F and 98 to 127,
p < 0.0008 in P). The following parameters improved only
in group F: LDL cholesterol (146 to 134, p < 0.027), Apolipoprotein
A-1 (105 to 139, p < 0.001), body mass index (24.9 to 24.5,
p < 0.03) and waist circumference (37.2 to 36.7, p < 0.03).
Total cholesterol, VLDL cholesterol, triglycerides, hip circumference,
W:H ratio, exercise time and blood sugar were unchanged in both
groups. CONCLUSIONS: Fibernat is well tolerated, safe and had
favorable effects on LDL cholesterol, Apolipoprotein A-1, body
mass index and waist circumference.
- Clinical Trial
- Randomized Controlled Trial